Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02396732 · ClinicalTrials.gov registry record · Phase 4
Aspirin and Enoxaparin for VTE in Trauma
A Phase 4 study, sponsored by University of Miami.
- Terminated
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
NCT02396732 is a Phase 4 study that was terminated before completion, run by University of Miami. The registered enrollment target is 31 participants.
The verdict
NCT02396732, a Phase 4 study, was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the addition of antiplatelet therapy (i.e. aspirin) to low-molecular-weight-heparin (i.e. enoxaparin) will decrease the incidence of venous thromboembolism (VTE) in high-risk critically injured patients. The investigators further aim to determine the safety and efficacy of dual thromboprophylaxis with aspirin and enoxaparin for decreasing the incidence of VTE after trauma.
Interventions
- DRUG Aspirin
- DRUG Enoxaparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2016-02 |
| Est. Completion | 2018-05-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02396732
The ClinicalTrials.gov registry entry for NCT02396732 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aspirin is the first listed.
NCT02396732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02396732 about?
NCT02396732 is a clinical study titled "Aspirin and Enoxaparin for VTE in Trauma". The purpose of this study is to determine if the addition of antiplatelet therapy (i.e. aspirin) to low-molecular-weight-heparin (i.e. enoxaparin) will decrease the incidence of venous thromboembolism (VTE) in high-risk critically injured patients. The investigators further aim to determine the safe...
What is the current status of trial NCT02396732?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2016-02. Estimated completion is 2018-05-15.
What interventions are being tested in trial NCT02396732?
The interventions under investigation include: Aspirin (DRUG), Enoxaparin (DRUG).
Who is sponsoring clinical trial NCT02396732?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.